The authorization is for R&D of a second-generation influenza vaccine.
BiondVax Pharmaceuticals Ltd. (TASE:BNDX) has obtained an Office of the Chief Scientist grant to develop a second-generation influenza vaccine. The Chief Scientist will provide up to NIS 2.4 million, amounting to half of the program's NIS 4.8 million budget. The Chief Scientist has already transferred NIS 1.7 million to the company.
BiondVax is developing an innovative universal influenza vaccine to create multi-season/multi-strain and long-term protection against a variety of flu viruses. The vaccine is currently undergoing Phase I human clinical trials.
BiondVax's share was unchanged at NIS 0.28 today.
Published by Globes [online], Israel business news - www.globes-online.com - on April 21, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009